Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world settingTakuya Sho, Naoya Sakamoto, Goki Suda et al.|JGH Open|2019Cited by 45
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteriaTakuya Sho, Naoya Sakamoto, Goki Suda et al.|Hepatology Research|2020Cited by 44
Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity testTakanori Teshima, Akio Mori, Hiroshi Iwasaki et al.|International Journal of Hematology|2019Cited by 5
Pretreatment evaluation of fluorescence resonance energy transfer‐based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinibTakeshi Kondo, Yoichiro Fujioka, Masumi Tsuda et al.|Cancer Science|2018Cited by 3